Check hepatic function before starting treatment every 1-2 wk for the 1st 2 mth after commencement & then every 3 mth during treatment. Monitor serum cholesterol & triglycerides especially in high-risk patients (disturbances of lipid metabolism, DM, obesity, alcoholism) & during long-term treatment. Frequently check blood sugar levels in early stages of treatment. Periodically perform appropriate exams for possible ossification abnormalities in adults. Monitor growth parameters & bone development in childn. Psychiatric disorders eg, depression, depression aggravated, anxiety & mood alterations. Patients w/ history of depression; monitor for signs of depression. Decreased night vision; patients driving or operating any vehicle at night. Carefully monitor for visual problems. Women of childbearing age must not ingest alcohol; avoid ethanol for 2 mth after cessation of therapy. Low-dose progesterone prep may be an inadequate method of contraception during therapy. Minimal, if any, risk of teratogenic effects for male patients. Not to be given to nursing mothers.